GAITHERSBURG, Md., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that it will present data from recent preclinical studies of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Nanoparticle Vaccine) at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C., September 5-9, 2014 at the Walter E. Washington Convention Center.
The presentation numbers, titles, dates and times are listed below:
Poster Session 024: I-314b. "Development and Characterization of Recombinant RSV F Nanoparticle Vaccine Induced Monoclonal Antibody"
[Exhibit Hall B, Saturday, September 6, 2014 from 12:00 to 2:00 pm]
Slide Session Number 077: I-649. "Immunization of Pregnant Baboons with the RSV F Nanoparticle Vaccine Protects Infant Baboons Challenged with Respiratory Syncytial Virus in a Comparable Manner to Infants Prophylaxed with Palivizumab"
[Meeting Room 209A, Sunday, September 7, 2014 from 8:45 to 9:00 am]
Novavax, Inc. (NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.
- Health Care Industry
- Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer